Losartan Effects on Emphysema Progression

Emphysema Clinical Trial

— LEEP  

Official title:

Losartan Effects on Emphysema Progression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02696564
• Other study ID #: U01HL128951
• Status: Completed
• Phase: Phase 4
• Start date: May 23, 2017
• Est. completion date: June 30, 2021

Study information

• Verified date: May 2022
• Source: JHSPH Center for Clinical Trials
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized, parallel, placebo controlled trial to evaluate the effect of 100mg/day losartan on the progression of emphysema as measured by quantitative HRCT compared to placebo

.

Description:

This is a trial designed to test if a treatment, losartan, may decrease the progression of Chronic Obstructive Pulmonary Disease (COPD). Losartan is an angiotensin receptor blocking agent, commonly used as an antihypertensive agent, which has been shown to alter cardiac remodeling after myocardial infarction and renovascular remodeling in diabetes-mellitus. In this trial participants with mild to severe COPD, with Computed Tomography (CT) evidence of emphysema (5-35% of voxels with < -950 Hounsfield Units), will be randomly assigned to receive 100mg/day of losartan or placebo for 48 weeks. The primary outcome measure will be the rate of progression of emphysema, quantified as the percent of lung voxels with a density less than -950 HU as measured by High Resolution CT (HRCT, from baseline to 48 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 220
• Est. completion date: June 30, 2021
• Est. primary completion date: March 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Mild to severe COPD: Ratio of forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) less than or equal to 0.70, FEV1 20-80% of predicted

• Current or former smoker

• HRCT scan with 5-35% of voxels with density less than -950 Hounsfield Units (HU)

• Ability to understand and willingness to sign consent documents

Exclusion Criteria:

• Current therapy with angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)

• Known intolerance to ACE inhibitor or ARB

• History of angioedema

• Conventional indication for ACE inhibitor or ARB (e.g., history of myocardial infarction, known cardiomyopathy)

• Renal insufficiency (GFR <30 mL/min by Cockcroft-Gault calculation)

• Current regular use of NSAIDs defined as daily use 5 or more days of the week for more than one month

• Potassium supplementation or serum potassium level of 5.0 milliequivalents (mEq)/dL or higher at V1

• Current use of a potassium sparing diuretic

• COPD exacerbation requiring treatment within 6 weeks at V1

• Chronic systemic corticosteroid use of more than 10mg/day of prednisone

• Resting SpO2 <89% on 2 L nasal cannula continuous flow; unless at altitude > 4,000 feet, then resting oxygen saturation (SpO2) <89% on 4 L N C continuous flow

• Untreated arterial hypertension (systolic blood pressure greater than140 mm Hg, diastolic blood pressure greater than 90 mm Hg)

• Blood pressure less than 90 mm Hg systolic or 60 mm Hg diastolic while standing or sitting

• Known unilateral or bilateral renal artery stenosis higher than 70%

• Previous lung resection surgery

• Evidence of interstitial, occupational or chronic infectious lung disease

• Changes to chest that preclude adequate HRCT imaging (e.g. Metallic objects in the chest such as shrapnel or pacemaker leads)

• For women of child bearing potential, positive pregnancy test or unwillingness to use two methods of birth control or abstinence for the duration of the study

• Major chronic illnesses which in the judgment of the study physician would interfere with participation in the study e.g. including but not limited to: cardiac, renal, hepatic (LFTs more than 2.5x normal upper limit), neurological, psychiatric, endocrine or neoplastic diseases, uncontrolled diabetes, uncontrolled HIV infection or other immune system disorder, hyperthyroidism, seizure disorders, non-skin cancer, rheumatic diseases

• Failure to keep screening appointments or other indicators of non-adherence

• Inability to be contacted by telephone

• Intention to leave area within 12 months

Related Conditions & MeSH terms

• Emphysema
• Pulmonary Emphysema

Intervention

Drug:
• Losartan
50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated
• Placebo
one capsule per day for two weeks, followed by two capsules per day for 46 weeks

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	Northwestern University	Chicago	Illinois
United States	Rush University Medical Center	Chicago	Illinois
United States	University of Chicago Hospitals	Chicago	Illinois
United States	University of Illinois at Chicago	Chicago	Illinois
United States	Vermont Lung Center at The University of Vermont	Colchester	Vermont
United States	Western Connecticut Health Network	Danbury	Connecticut
United States	National Jewish Medical and Research Center	Denver	Colorado
United States	Duke University Medical Center	Durham	North Carolina
United States	Baylor College of Medicine	Houston	Texas
United States	St. Vincent Hospital and Health Care Center, Inc.	Indianapolis	Indiana
United States	University of Florida College of Medicine	Jacksonville	Florida
United States	University of Kansas Medical Center	Kansas City	Kansas
United States	Louisiana State University	New Orleans	Louisiana
United States	Columbia University Medical Center	New York	New York
United States	Mount Sinai National Jewish Health Respiratory Institute; Icahn School of Medicine	New York	New York
United States	New York University School of Medicine	New York	New York
United States	Weill Cornell Medicine	New York	New York
United States	Temple University	Philadelphia	Pennsylvania
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	St. Louis Asthma Clinical Research Center - Washington University School of Medicine	Saint Louis	Missouri
United States	St. Louis University School of Medicine	Saint Louis	Missouri
United States	University of California at San Diego	San Diego	California
United States	University of California at San Francisco	San Francisco	California
United States	Pacific Northwest Airways - VA Puget Sound Healthcare System	Seattle	Washington
United States	University of South Florida	Tampa	Florida
United States	University of Arizona	Tucson	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
JHSPH Center for Clinical Trials	University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Mean pct950	change in percentage of voxels with density less than -950 Hounsfield Units	48 weeks
Secondary	Change From Baseline in Pre-bronchodilator FEV1 Percent Predicted	Change from the first visit to the final visit in a spirometry (breathing test) measure: forced expiratory volume in one second (FEV1). The test is administered without the participant taking any bronchodilator medication. The FEV1 is compared to standard predicted values in the US population for each individual based on their height, gender, and ethnic group; the result is given as percent of predicted value.	48 weeks
Secondary	Change From Baseline in Post-bronchodilator FEV1 Percent Predicted	Change from the first visit to the final visit in a spirometry (breathing test) measure: forced expiratory volume in one second (FEV1). This test is performed after the participant is given bronchodilator medications. The FEV1 is compared to standard predicted values in the US population for each individual based on their height, gender, and ethnic group; the result is given as percent of predicted value.	48 weeks
Secondary	Change From Baseline in CAT Score	Change from the first visit to the final visit in the participant's COPD Assessment Test (CAT) score. The CAT is an 8-item questionnaire assessing the impact of COPD on health status. CAT scores range from 0 to 40, with higher scores indicating a more severe impact of COPD on a patient's life.	48 weeks
Secondary	Change From Baseline in SGRQ Score: Total	Change from the first visit to the final visit in participants' score on the St George's Respiratory Questionnaire - COPD. The St George's Respiratory Questionnaire for COPD patients (SGRQ-C) is a 40-item questionnaire designed to measure impact on overall health, daily life, and perceived well-being in patients with COPD. The SGRQ-C includes three categories: Symptoms (frequency and severity), Activities caused or limited by breathlessness, and Impacts on social and psychological functioning caused by airways disease. The total score and scores for each category range from 0 to 100, with higher scores indicating more limitations.	48 weeks
Secondary	Change From Baseline in SGRQ Score: Symptoms	Change from the first visit to the final visit in participants' scores on the symptom-related questions on the St Georges Respiratory Questionnaire-COPD. The St George's Respiratory Questionnaire for COPD patients (SGRQ-C) is a 40-item questionnaire designed to measure impact on overall health, daily life, and perceived well-being in patients with COPD. The SGRQ-C includes three categories: Symptoms (frequency and severity), Activities caused or limited by breathlessness, and Impacts on social and psychological functioning caused by airways disease. The total score and scores for each category range from 0 to 100, with higher scores indicating more limitations.	48 weeks
Secondary	Change From Baseline in SGRQ Score: Activity	Change from the first visit to the final visit in participants' scores on the activity-related questions on the St Georges Respiratory Questionnaire-COPD. The St George's Respiratory Questionnaire for COPD patients (SGRQ-C) is a 40-item questionnaire designed to measure impact on overall health, daily life, and perceived well-being in patients with COPD. The SGRQ-C includes three categories: Symptoms (frequency and severity), Activities caused or limited by breathlessness, and Impacts on social and psychological functioning caused by airways disease. The total score and scores for each category range from 0 to 100, with higher scores indicating more limitations.	48 weeks
Secondary	Change in SGRQ Score: Impact	Change from the first visit to the final visit in participants' scores on the impact-related questions on the St Georges Respiratory Questionnaire-COPD. The St George's Respiratory Questionnaire for COPD patients (SGRQ-C) is a 40-item questionnaire designed to measure impact on overall health, daily life, and perceived well-being in patients with COPD. The SGRQ-C includes three categories: Symptoms (frequency and severity), Activities caused or limited by breathlessness, and Impacts on social and psychological functioning caused by airways disease. The total score and scores for each category range from 0 to 100, with higher scores indicating more limitations.	48 weeks
Secondary	Change From Baseline in mMRC Dyspnea Scale	Change from the first visit to the final visit in participants' scores on the modified Medical Research Council dyspnea scale. The modified Medical Research Council dyspnea scale (mMRC) is a self-rating tool to measure how much breathlessness affects someone's day to day activities. Scores are between 0 and 4, with higher scores indicating more severe breathlessness.	48 weeks
Secondary	Change From Baseline in PROMIS-20a T-score	Change from the first visit to the final visit in participants' scores on the Patient-Reported Outcome Measures Information System (PROMIS) Physical Function assessment. The Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form 20a is a 20-item questionnaire used to indicate a patient's ability to perform activities of daily living, such as bathing, dressing, and commuting. Raw scores from this questionnaire are compared to a reference population to create a "T-score". The general US population is the reference population. In this T-score metric, 50 indicates the population mean with a standard deviation of 10. Higher scores mean better outcomes (more ability to do activities of daily living)	48 weeks